GHRS Projected Dividend Yield
Ord/GH Research PLC ( NASDAQ : GHRS )GH Research PLC is a clinical-stage biopharmaceutical company. Co. is engaged in offering treatment for psychiatric and neurological disorders. Co.'s pipeline includes GH001, GH002 and GH003. Co. focuses on developing its 5- Methoxy-N, N-Dimethyltryptamine, (5-MeO-DMT), therapies for the treatment of patients with Treatment Resistant Depression (TRD). Its product candidate, GH001, is formulated for 5-MeO-DMT administration via an inhalation approach. With GH001, the Co. has completed two Phase 1 healthy volunteer clinical trials and a Phase 1/2 clinical trial in patients with treatment-resistant depression (TRD). 20 YEAR PERFORMANCE RESULTS |
GHRS Dividend History Detail GHRS Dividend News GHRS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |